Table 2.
Clinical manifestation of patients who reached to end–stage renal disease
| Patient A | Patient B | Patient C | Patient D | Patient E | Patient F | |
|---|---|---|---|---|---|---|
| Body mass index (kg/m2) |
24.6 |
Unknown |
18.3 |
21.6 |
23.2 |
21.4 |
| Blood pressure (mmHg) |
110/10 |
130/90 |
100/70 |
110/70 |
110/70 |
100/60 |
| Blood urea nitrogen (mg/dL) [10-26] |
9 |
17 |
12 |
12 |
12 |
NA |
| Serum creatinine (mg/dL) [0.70–1.40] |
1.00 |
1.20 |
0.90 |
1.20 |
0.70 |
1.30 |
| Creatinine clearance (mL/min) |
78.5 |
NA |
84 |
87 |
NA |
66 |
| eGFR (mL/min/1.73 m2) |
72.1 |
74.1 |
77.1 |
82.7 |
152.4 |
74.6 |
| Serum albumin (g/dL) [3.3–5.2] |
4.6 |
4.9 |
3.5 |
4.4 |
4.0 |
NA |
| Proteinuria (g/day) |
0.21 |
0.22 |
0.35 |
0.34 |
0.18 |
0.20 |
| WHO grade |
III |
II |
II |
III |
III |
NA |
| Global sclerosis (N/Glom No) |
0/19 |
1/15 |
0/8 |
2/32 |
1/35 |
0/5 |
| Segmental sclerosis (N/Glom No) |
0/19 |
0/15 |
0/8 |
2/32 |
2/35 |
0/5 |
| Crescent formation (N/Glom No) |
0/19 |
0/15 |
0/8 |
0/32 |
0/35 |
0/5 |
| Mesangial proliferation |
None |
Mild |
None |
Mild |
Mild |
Moderate |
| Tubular atrophy |
Mild |
None |
None |
Moderate |
Mild |
NA |
| Interstitial fibrosis |
None |
None |
None |
Mild |
Mild |
NA |
| Interstitial inflammation |
Mild |
None |
Mild |
Moderate |
None |
NA |
| Vascular change |
None |
None |
None |
None |
None |
None |
| Time to ESRD (months) | 153 | 224 | 101 | 100 | 58 | 159 |
Continuous variables are presented by median (interquartile range). Categorical variables are presented by frequency (percentage). eGFR, estimated glomerular filtration rate; RAS, renin–angiotensin system.